Accès ouvert

IDH Mutations in AML Patients; A higher Association with Intermediate Risk Cytogenetics

Article scientifique 2020 Anglais

Résumé

OBJECTIVE: IDH mutations diversely affect the prognosis of cyogenetically normal acute myeloid leukemia (CN-AML) adult patients. The aim of this study is to assess the frequency of IDH mutations and to evaluate its role in AML prognosis. METHODS: We have analyzed IDH1 and 2 mutations using High Resolution Melting curve analysis (HRM) in 70 denovo AML patients. RESULTS: The median age of AML patients is 40 years (16-75). Incidence of IDH mutations is 10/70 (14.3%); 2 (2.9%) IDH1 mutant and 8 (11.4%) IDH2 mutant. Median PB blasts of mutant IDH patients was 67.5% (25-96) vs. 44% (0-98) for wild type (p=0.065). Eight/10 (80%) mutant IDH patients had B.M blasts ≥50% vs. 2/10 (20%) <50% (p<0.001) and were classified as intermediate risk cytogenetics (p=0.020) with wild FLT3-ITD (p=0.001). Ten/10 (100%) mutant IDH patients showed wild NPM1 (p=0.049). Median OS of mutant IDH in the intermediate risk cytogenetics was 1.8 years (0.7-3.1) vs. 3.1 years (1.1-5.5) for wild IDH (p=0.05). CONCLUSION: IDH mutation is mainly associated with intermediate risk AML and when integrated in this specific subgroup displays a lower survival and can be considered an additional integrated molecular risk marker for AML prognosis. .

Citer ce document

Elnahass, Y., Badawy, R., Elrefaey, F., Nooh, H., Ibrahiem, D., Nader, H., Mahmoud, H., El-Metnawy, W. (2020). IDH Mutations in AML Patients; A higher Association with Intermediate Risk Cytogenetics. https://doi.org/10.31557/apjcp.2020.21.3.721

Accès au document

Voir sur le dépôt source

Ce document est hébergé sur son dépôt institutionnel d'origine.

Auteur(s)

Yasser Elnahass Ragia Badawy Fatma A Elrefaey Hend A. Nooh Dalia M. Ibrahiem Heba Nader Hossam K. Mahmoud Wafaa El-Metnawy

Statistiques

Consultations : 1

Téléchargements : 0